RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects.

Area of Science:

• Hepatology and Viral Immunology
• Molecular Therapeutics and RNA Biology

Background:

• Chronic hepatitis B (CHB) poses a significant global health burden, necessitating lifelong treatment for many patients.
• Current treatments, primarily nucleoside analogues, manage but do not cure CHB, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review the emerging potential of RNA interference (RNAi) therapeutics for treating chronic hepatitis B.
• To highlight recent advancements in RNAi-based strategies targeting hepatitis B virus (HBV) replication.

Main Methods:

• Exploration of RNA interference mechanisms, specifically small interfering RNA (siRNA), for targeting viral RNA.
• Review of current RNAi therapeutic candidates in development for CHB treatment.
• Analysis of strategies for enhancing siRNA stability and delivery.

Main Results:

• RNAi therapeutics, particularly siRNA, demonstrate potential in inhibiting HBV replication.
• Several candidates have shown efficacy in reducing hepatitis B surface antigen (HBsAg) levels.
• Some studies report sustained HBsAg loss following therapy cessation, indicating a potential for functional cure.

Conclusions:

• RNAi therapy represents a dynamic and promising frontier for developing effective, sustained treatments for CHB.
• Ongoing research into modifications, delivery vectors, and specific siRNA candidates is crucial for clinical advancement.